New manager for Biogen Switzerland AG

With immediate effect, Graham Dorey is now General Manager responsible for the strategic management of Biogen Switzerland AG. He has held various positions in the company since 2019.

According to a communication from the company, Graham Dorey has taken over the position of General Manager for Biogen Switzerland AG with immediate effect. He thereby succeeds Katharina Gasser, who has filled the position from 2018.

Graham Dorey has been with Biogen from 2019, and started as Commercial Head of Multiple Sclerosis (MS). From March 2022 on, he has been Head of Commercial Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA) and Rare Diseases and has been Managing Director ad interim from June 2022.

Graham Dorey                  Bild: PD

Prior to joining Biogen, he worked for leading pharmaceutical companies, including Sanofi, MSD and Novo Nordisk, where he held sales and marketing positions. Graham Dorey brings broad international experience with him: after studying at the London School of Pharmacy and an MBA at the London Business School, he held various management positions in the UK, France and Switzerland.

The therapeutic focus was on cardiovascular diseases, diabetes, rheumatology and rare diseases. Parallel to his work at Biogen, he completed his Master of Public Health at the University of Zurich in 2020.

Working with his team, he aims to expand and solidify Biogen's position as a pioneer in neuroscience. The company is to play an active role in shaping the future of the healthcare industry. In concrete terms, this means creating added value for the lives of patients in Switzerland.